Clinical Trials Logo

Filter by:
NCT ID: NCT05987358 Not yet recruiting - Biliary Carcinoma Clinical Trials

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Start date: October 2023
Phase: Phase 3
Study type: Interventional

This study used a randomized, controlled, double-blind, multicenter Phase III clinical design with overall survival (OS) as the primary endpoint. About 165 patients with advanced biliary carcinoma were enrolled and randomly assigned to the experimental group and the control group in a 2:1 ratio to receive TQB3454 tablets or the placebo, respectively, to evaluate the efficacy and safety of TQB3454 tablets in the treatment of advanced biliary carcinoma.

NCT ID: NCT05986981 Not yet recruiting - Solid Tumor, Adult Clinical Trials

MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers

Start date: August 2023
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, single-center, open, single-arm, exploratory study of a therapeutic cancer vaccine for the treatment of advanced solid tumors. A dose-escalation trial is being conducted in subjects diagnosed with advanced solid tumors to evaluate the safety and tolerability of the cancer vaccine in subjects with advanced solid tumors and to preliminarily evaluate the efficacy of the tumor vaccine in subjects with advanced solid tumors.

NCT ID: NCT05985993 Not yet recruiting - Clinical trials for Negative Symptoms of Schizophrenia

Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Based on the current background and our previous studies, TUS has been proved that rTUS intervention could induce long-term potentiation like (LTP-like) plasticity and neuromodulate the brain cortex in schizophrenia patients. rTUS over the left dorsolateral prefrontal cortex (DLPFC) can alleviate the negative symptoms in schizophrenia. In this double-blind, randomized, sham-controlled study, the efficacy of different treatment options and mechanisms of low-intensity rTUS on negative symptoms will be investigated.

NCT ID: NCT05985707 Not yet recruiting - Clinical trials for HER2-positive Colorectal Cancer

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Start date: August 15, 2023
Phase: Phase 2
Study type: Interventional

The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 (a PD-L1/CTLA-4 targeted bispecific antibody).

NCT ID: NCT05985408 Not yet recruiting - Heart Failure Clinical Trials

LVSP Based CRT vs. RVAP Based CRT

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

To find out whether left ventricular septal pacing (LVSP)-based cardiac resynchronization therapy (CRT) is superior to right ventricular apical pacing (RVAP)-based CRT in patients with failed left bundle branch pacing at the beginning of chronic heart failure.

NCT ID: NCT05985252 Not yet recruiting - Rectal Neoplasms Clinical Trials

Virtual Ileostomy Versus Conventional Loop Ileostomy

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This study aimed at comparing the Comprehensive Complication Index (CCI), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with ghost ileostomy versus conventional loop ileostomy after low anterior resection for rectal cancer.

NCT ID: NCT05984550 Not yet recruiting - Clinical trials for Enhance Immune Function

The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.

Start date: August 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to investigate the changes in adult peripheral blood immune cell subpopulations, subpopulations, and cell functional status before and after intervention with Nicotinamide Mononucleotide (Vital NAD ) as NAD+ supplement for a certain period of time。To Explore and validate the biological functions of Nicotinamide Mononucleotide (Vital NAD ) of rejuvenation of the Peripheral blood immune cells of Adults.

NCT ID: NCT05984303 Not yet recruiting - Clinical trials for Decompensated Cirrhosis

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)

Start date: August 30, 2023
Phase: Phase 1
Study type: Interventional

This clinical trial is a Phase 1, multiple administration, dose-escalasion clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.

NCT ID: NCT05983796 Not yet recruiting - 18F-HER2 PET Clinical Trials

18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

Start date: August 10, 2023
Phase: N/A
Study type: Interventional

This is a open-label, one-arm, multicenter study aimed to explore the efficacy and safety of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

NCT ID: NCT05983094 Not yet recruiting - Breast Cancer Clinical Trials

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.